ArticleNature communications2026
Engineering LmrR protein for L-proline-based asymmetric aldol biocatalysis.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
L-Proline is a powerful organocatalyst widely applied in asymmetric synthesis due to its secondary amine functionality. However, in proteins, this functional group is locked in peptide bonds, rendering proline catalytically inactive. Natural enzymes that leverage L-proline-based catalysis are exceedingly rare. Here, we engineer the nonenzymatic protein scaffold LmrR into a new-to-nature biocatalyst by exposing its native L-proline residue at the N-terminus to catalyze enantioselective aldol reactions. Through rational design, protein engineering, and reaction optimization, we develop an engineered LmrR variant that achieves up to 99% conversion and >99% enantiomeric excess across a range of aromatic and heteroaromatic aldehyde substrates. Our findings reveal a unique strategy for unlocking dormant catalytic potential in natural amino acids and protein scaffolds, providing an applicable approach to create tailored, L-proline-based enzymes for asymmetric synthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.